Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients

Pamela Biondani, Elena Verzoni, Valter Torri, Luca Porcu, Paolo Grassi, Isabella Testa, Filippo De Braud, Giuseppe Procopio

Research output: Contribution to journalArticle

Abstract

Background: Only scanty data are available to evaluate the impact of sequential TKIs on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). This retrospective study investigated the efficacy of the sequence sorafenib-sunitinib (SO-SU) and vice versa (SU-SO) in a real-life scenario. Patients and Methods: Median progression free-survival (PFS) and OS were evaluated. The correlation between PFS and OS was also assessed. Results: In total, 104 patients received SO-SU and 21 (16.8%) SO-SU. No differences in PFS or OS were observed (PFS for SO-SU=26.1 months, and for SUSO= 20.0 months; OS=35.3 and 27.0 months, respectively). For both sequences, only a weakly-positive correlation between PFS and OS was observed. Conclusion: Our data support the use of the sequence of the two TKIs in a real-life setting. No strong evidence of a correlation between PFS and OS was observed.

Original languageEnglish
Pages (from-to)2395-2398
Number of pages4
JournalAnticancer Research
Volume34
Issue number5
Publication statusPublished - May 1 2014

Keywords

  • Overall survival
  • Progressionfree survival
  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients'. Together they form a unique fingerprint.

  • Cite this